As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies
Rhea-AI Summary
NanoViricides (NYSE American: NNVC) has proposed a Phase II clinical trial of its NV-387 oral gummies to treat the current Bundibugyo ebolavirus outbreak in the DRC. NV-387 is a broad-spectrum antiviral given orally, designed to target host-cell attachment mechanisms and reduce viral escape across multiple filoviruses.
AI-generated analysis. Not financial advice.
Positive
- Proposed Phase II trial of NV-387 oral gummies for Bundibugyo ebolavirus in DRC
- NV-387 formulated as room‑temperature stable oral gummies, simplifying transport and administration in low‑resource settings
- Company holds worldwide exclusive licenses for multiple viral indications, supporting a diversified antiviral pipeline anchored by NV-387
Negative
- Company states it cannot project IND filing dates for its drugs due to reliance on external collaborators and consultants
- NanoViricides cautions there is no assurance any drug candidate will demonstrate sufficient safety and effectiveness for approval
News Market Reaction – NNVC
On the day this news was published, NNVC gained 6.16%, reflecting a notable positive market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $33.60M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
NNVC is down 8% while tracked biotech peers show mixed moves (e.g., QTTB -5%, FBLG -5.61%, LIXT +2.49%). Momentum scanner also flags both rising (RNTX +5.98%) and falling (GDTC -5.43%) names, supporting a stock-specific move rather than a sector-wide trend.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 15 | 10-Q & trial update | Neutral | -14.9% | Q1 2026 report with NV-387 Phase II MPox progress and Measles ODD. |
| May 04 | Measles ODD granted | Positive | +15.4% | US FDA Orphan Drug Designation for NV-387 in Measles with noted benefits. |
| Apr 01 | MPox Phase II to start | Positive | +4.7% | Announcement that NV-387 MPox Phase II trial in DRC will begin soon. |
| Mar 11 | Conference & manufacture | Positive | +18.3% | Completion of NV-387 oral gummies Phase II product and conference presentation. |
| Feb 12 | MPox ODD filing | Positive | -7.9% | Filing for Orphan Drug Designation for NV-387 in MPox with Phase I data. |
Clinical and regulatory NV-387 updates have often produced sharp but mixed price reactions, with both strong rallies and sizable selloffs following similar Phase II and orphan-designation headlines.
Over the last few months, NNVC has repeatedly highlighted NV-387 progress. Key milestones include completion of Phase I, multiple moves toward Phase II trials for MPox and respiratory infections, and several Orphan Drug Designation applications and grants across MPox and Measles (e.g., events on Feb 12, Apr 1, May 4, and May 15, 2026). These same-tag updates show that clinical and regulatory steps for NV-387 can trigger both double‑digit gains and losses, providing a volatile backdrop for today’s proposed Ebola Phase II trial news.
Historical Comparison
In the past months, NNVC issued 5 NV-387 clinical-trial updates averaging a 3.1% move, with both strong rallies and selloffs. Today’s Ebola Phase II proposal fits this pattern of volatile reactions around development milestones.
Same-tag events show NV-387 moving from Phase I completion into multiple Phase II programs (MPox, respiratory infections) while securing Orphan Drug Designations in MPox and Measles, building a multi-indication development path.
Regulatory & Risk Context
On June 5, 2026, the company filed an S-3 shelf to offer up to $50,000,000 of securities, including common and preferred stock, debt, warrants, rights and units, with terms to be set in future prospectus supplements.
Market Pulse Summary
The stock moved +6.2% in the session following this news. A strong positive reaction aligns with prior NV-387 clinical milestones, where some Phase II and orphan-designation headlines triggered double‑digit gains (e.g., up to 18.32%). However, NNVC also saw sharp drops after good news, underscoring event-driven volatility and financing needs highlighted in recent SEC filings. The new $50,000,000 S-3 shelf adds flexibility for future capital raises, which could influence how sustainable any large rally becomes.
Key Terms
phase ii clinical trial medical
bundibugyo ebolavirus medical
public health emergency of international concern ("pheic") regulatory
monoclonal antibody medical
remdesivir medical
case fatality rate (cfr) medical
broad-spectrum antiviral medical
AI-generated analysis. Not financial advice.
SHELTON, CT / ACCESS Newswire / June 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, NanoViricides announces that it has proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus to the Committee in Charge in the Democratic Republic of Congo (DRC).
The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source[1], such as fruit bats.
The outbreak which was declared a Public Health Emergency of International Concern ("PHEIC") by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The WHO has revised the number of confirmed cases to 452 and deaths to 82 in DRC plus 19 confirmed cases and 2 deaths in neighboring Uganda[2]. These are the latest numbers after the WHO had previously reported 906 suspected cases and 220 suspected deaths in DRC; the latter numbers have been revised after expanded testing. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk[3].
While there is currently minimal risk of Ebola in the USA, the CDC's mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths in the next three months alone, rivaling the largest update to date in 2014-2016[4].
There are no approved vaccines or treatments against the Bundibugyo virus.
"We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is spreading rapidly in Africa," said Anil R. Diwan, PhD, adding, "It is an oral drug, in contrast to other infusions, which makes for easy scalability of NV-387 treatment in this lethal disease theater to treat the most number of patients while requiring the least amount of healthcare resources. Thus evaluating if NV-387 treatment works is of paramount importance to combat this outbreak."
A new antibody cocktail, MBP134 (ZMapp), a monoclonal antibody, Maftivimab (Regeneron), and a nucleotide analog Remdesivir are being considered for treatment.
All of these potential treatments require I.V. infusions with most requiring multiple infusions. This is very difficult to implement in the low resource environment, complicated with the lethal disease scenario of extreme isolation suites, and healthcare workers covered with PPE. Further, monoclonal antibodies are highly specific to the strain of virus and usually are not effective against unrelated strains.
Infusions are certainly not scalable in a large outbreak scenario if this Ebola virus outbreak continues to grow, as has been widely expected.
Further, viruses readily escape antibodies after exposure to the drugs.
In contrast, NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.
This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.
Additionally, NV-387 was previously found to be superior to remdesivir in a lethal animal model of a viral disease. The Company believes this superiority of NV-387 is very likely to extend to the current novel Bundibugyo ebolavirus strain.
Further, it is highly unlikely that viruses can escape NV-387, because this drug mimics the features on host cells that the viruses continue to require even as they mutate or evolve in the field.
Additionally, NV-387 Oral Gummies drug product is ready to be shipped to DRC for the impending Phase II clinical trial of NV-387 as a Treatment for Mpox. It will thus be immediately locally available to combat the Ebola outbreak if it shows effectiveness against Ebola Bundibugyo in patients.
These factors should make NV-387 a strong contender for conducting Phase II clinical trials as a treatment of the Bundibugyo Virus (BDBV) infection and the resulting Bundibugyo Virus Disease (BVD).
NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate proteoglycan that over 90
All Ebola viruses utilize HSPG as the attachment receptor, followed by entry into the cell inside endosomes. The virus substantially dismantles in the endosome and hitches a cognate receptor called NPC1 to enter the cytoplasm where the next steps in its replication begin.
Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.
NV-387 is available as an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.
If NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses or all filoviruses; that would be a game changer for pandemic preparedness.
Currently there is no treatment or vaccine for the Bundibugyo virus. All previous efforts have been focused on vaccines and antibodies[5]. This has led to approval of therapies that are specific to the Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.
The WHO declared a Public Health Emergency of International Concern (PHEIC) for the Bundibugyo outbreak in Eastern DRC, with two cases in Uganda in travelers from Congo, on May 17, 2026[6]. The outbreak itself was declared on May 15, although the initial or "patient zero" case likely occurred in April, 2026. This delay was primarily because of the cases occurring in clusters in multiple remote locations that had limited reporting capabilities.
Three American Doctors working at hospitals in the Ebola affected area were exposed to the BDBV. One of them was moved to Germany and treated in hospitalized setting. He has recovered after approximately 15 days and has been released. His wife (another doctor) did not develop symptoms, and she and their children have been united in Germany. The third doctor was moved to the Czech republic. It is believed that he did not develop symptoms.
The US Government is active in ensuring that suspected or confirmed ebolavirus cases do not enter the general population in the USA. To this end, travel from DRC has been restricted, and suspect travelers are directed to screening at specific airports and may be quarantined.
The case fatality rate of ebolaviruses has generally been around
An irony is that because of the high case fatality rate (CFR) approaching
With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.
"Only safe and effective broad-spectrum antiviral drugs that can effectively combat most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses," commented Dr. Diwan, adding, "NV-387 is the only drug with such potential that is in clinical development today, to the best of our knowledge."
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
Source: NanoViricides, Inc.
[5]Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.
SOURCE: NanoViricides
View the original press release on ACCESS Newswire